---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacodynamics"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacodynamics. Topics: Reduction of pMARCKS and pPKC delta in tumor biopsies and peripheral blood mononuclear cells in the first-in-human study, No association between the extent of pMARCKS or pPKC delta suppression and dose group in the first-in-human study, RasGRP3 and DUSP6 expression in the first-in-human study, Preclinical tumor regression in the 92.1 uveal melanoma xenograft model, and 2 further topics. 6 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Reduction of pMARCKS and pPKC delta in tumor biopsies and peripheral blood mononuclear cells in the first-in-human study

> “LXS196 reduced pMARCKS and phosphorylated PKC delta (pPKC delta), suggesting target engagement in on-treatment tumour biopsies.”
> “Reduction in pPKC delta in PBMCs was observed within 6 h post-dose at all dose levels (Fig. 2a, b).”
> “The mean (range) reduction in percentage change from baseline to C1D15 (normalised ratio) for pPKC delta and pMARCKS was −68.1 (−91.4, −28.6) and −39.7 (−89.7, 199), respectively.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-2"></a>

### No association between the extent of pMARCKS or pPKC delta suppression and dose group in the first-in-human study

> “A decrease in pMARCKS/MARCKS was observed by C1D15 in patient tumour samples; however, no clear associations were detected between the extent of pMARCKS suppression and LXS196 treatment group.”
> “Consistent with this, a decrease in pPKCd was observed by C1D15, but no correlation was seen between the extent of suppression and the LXS196 treatment group.”
> “The decrease in pPKCd was also observed in PBMCs, which are not expected to carry mutations in the GNAQ/GNA11 pathway.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-3"></a>

### RasGRP3 and DUSP6 expression in the first-in-human study

> “RasGRP3 was decreased in some patients receiving LXS196 both QD and BID (Supplementary Fig. 2).”
> “Levels of RasGRP3 at screening and after treatment also correlate with the best percent change in tumour volume from baseline (Supplementary Fig. 2).”
> “MAPK pathway activity as measured by DUSP6 expression showed a trend towards suppression in the PR group (Supplementary Fig. 2).”
> “Exploratory analysis of RasGRP3 reveals a potential biomarker for predicting efficacy and evidence of a transcriptional regulatory feedback on RasGRP3 by PKC inhibition and warrants further investigation.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-4"></a>

### Preclinical tumor regression in the 92.1 uveal melanoma xenograft model

> “When assessed in the 92.1 human UM mouse xenograft model, LXS196 dosed as a single agent leads to tumour regression at doses below its maximum tolerated dose (MTD), in contrast to AEB071, which achieves only stasis in this model”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.2-5"></a>

### Preclinical synergy of darovasertib and crizotinib in the presence of hepatocyte growth factor

> “Addition of HGF alone significantly antagonized IDE196 activity at doses ≥1.23ng/ml.”
> “Crizotinib synergized strongly with IDE196 at clinically relevant doses (80nM) in MEL202 and MM28 in contrast to the 92.1 where mild or no synergy was observed.”
> “PD analysis showed that in the absence of HGF, IDE196 dose-dependently inhibited pERK, pMARCKS and pPKC-delta in all three cell lines.”
> “Addition of HGF dose-dependently induced pMET, pERK levels, pAkt and pPRAS40 levels in all cell lines which was not inhibited by IDE196.”
> “Addition of crizotinib alone or in combination with IDE196 strongly inhibited the activation of these pathways in these cell lines.”

Source: [Wagle et al. (2021)](https://aacrjournals.org/cancerres/article/81/13_Supplement/1343/667196/Abstract-1343-Preclinical-evaluation-of-a-PKC-and)

<a id="topic-2.1.2.6.2-6"></a>

### Crizotinib label: QTcF change from baseline in an ECG substudy

> “In an ECG substudy conducted in 52 patients with ALK-positive NSCLC, the maximum mean QTcF (corrected QT by the Fridericia method) change from baseline was 12.3 ms (2-sided 90% upper CI: 19.5 ms) following administration of XALKORI 250 mg orally twice daily.”
> “An exposure-QT analysis suggested a crizotinib plasma concentration-dependent increase in QTcF”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
